Add time:08/30/2019         Source:sciencedirect.com

SummaryBackgroundGlioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to assess the efficacy and safety of regorafenib in the treatment of recurrent glioblastoma.

We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers